Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402

Immunovant, Inc.

2024-Q3 EPS reported -$1.36

Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.
IMVT-1402 Phase 1 showed 74% IgG reduction with no/minimal albumin or LDL changes vs placebo.
Plans to start 4-5 potentially registrational IMVT-1402 programs by Mar 2025, 10 indications by Mar 2026.
Batoclimab Phase 3 MG data expected 2H 2024; TED data 1H 2025; Phase 2b CIDP data 2Q/3Q 2024.
R&D spend $48.3M in Q3, up from $42.3M, driven by IMVT-1402 development costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Immunovant, Inc. reported the fiscal third quarter ended December 31, 2023 results: net income Net loss was $51.4 million ($0.36 per common share), EPS $0.36 per common share.

Period: the fiscal third quarter ended December 31, 2023
Net income: Net loss was $51.4 million ($0.36 per common share)
EPS: $0.36 per common share
Result: reported results

Exact text from the filing

Net loss was $51.4 million ($0.36 per common share) for the three months ended December 31, 2023, compared to $63.2 million ($0.49 per common share) for the three months ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Immunovant, Inc. reported the fiscal nine months ended December 31, 2023 results: net income Net loss was $184.0 million ($1.36 per common share), EPS $1.36 per common share.

Period: the fiscal nine months ended December 31, 2023
Net income: Net loss was $184.0 million ($1.36 per common share)
EPS: $1.36 per common share
Result: reported results

Exact text from the filing

Net loss was $184.0 million ($1.36 per common share) for the nine months ended December 31, 2023, compared to $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Immunovant, Inc. filing history →

Source: SEC EDGAR

accession 0001764013-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.